Fariba Esmaeili

Fariba Esmaeili


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2021 in Journal of Biomaterials Science, Polymer Edition
Verified
Journal Article
Closed access
MAMahdi Aghajani
Mahdi Aghajani
FEFariba Esmaeili
Fariba Esmaeili
The protein/cell interactions with the surface at the blood-biomaterial interface generally control the efficiency of biomedical devices. A wide range of active processes and slow kinetics occur simultaneously with many biomaterials in healthcare applications, leading to multiple biological reactions and reduced clinical functions. In this work, we present a brief review of studies as the interface between proteins and biomaterials. These include mechanisms of resistance to proteins, protein-rejecting polyelectrolyte multilayers, and coatings of hydrophilic, polysaccharide and phospholipid nature. The mechanisms required to attain surfaces that resist adhesion include steric exclusion, water-related effects, and volume effects. Also, approaches in the use of hydrophilic, highly hydrated, and electrically neutral coatings have demonstrated a good ability to decrease cell adhesion. Moreover, amongst the available methods, the approach of layer-by-layer deposition has been known as an interesting process to manipulate protein and cell adhesion behavior. Graphical Abstract It is well known that the topography, chemical composition and charge of surface, hydrophilic or lipophilic ratio, mobility of functional groups, density and thickness of the modified layer and its adherence on the substrate, can affect the adsorption of proteins, surface contacting, and properties of polymers.

11 January 2022 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
RBReyhaneh Beiki
Reyhaneh Beiki
MKMahsa Khaghani
Mahsa Khaghani
FEFariba Esmaeili
Fariba Esmaeili
FDFariba Dehghanian
Fariba Dehghanian
The development of dopaminergic (DA) neurons is a very complex process, and a combination of extrinsic and intrinsic factors involves their differentiation. Transcription factor, Nurr1 plays an essential role in the differentiation and maintenance of midbrain DA neurons. Nurr1-based therapies may restore DA function in Parkinson's disease (PD) by replacing damaged cells with differentiated cells derived from stem cells. Providing tissue-specific microenvironments such as brain extract can effectively induce dopaminergic gene expression in stem cells. The present study aimed to investigate the combined effects of Nurr1 gene overexpression and a neonatal rat brain extract (NRBE) induction on dopaminergic differentiation of P19 stem cells. In order to neural differentiation induction, stably Nurr1-transfected cells were treated with 100 μg/ml of NRBE. The differentiation potential of the cells was then evaluated during a period of 1–3 weeks via various methods. The initial evaluation of the cells by direct observation under a light microscope and cresyl violet specific staining, confirmed neuron-like morphology in the differentiated cells. In addition, different molecular and cellular techniques, including real-time PCR, immunofluorescence, and flow cytometry, demonstrated that the treated cells expressed pan-neuronal and dopaminergic markers. In all experimental groups, neuronal phenotype with dopaminergic neuron-like cells characteristics mainly appeared in the second week of the differentiation protocol. Overall, the results of the present study revealed for the first time the synergistic effects of Nurr1 gene overexpression and possible soluble factors that existed in NRBE on the differentiation of P19 stem cells into dopaminergic neuron-like cells.

4 December 2015 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
ZMZahra Mehrfarjam
Zahra Mehrfarjam
FEFariba Esmaeili
Fariba Esmaeili
LSLeila Shabani
Leila Shabani
Esmaeil EbrahimieEsmaeil Ebrahimie
Esmaeil Ebrahimie

12 March 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
AAA. Amini
A. Amini
FEFariba Esmaeili
Fariba Esmaeili
MGM. Golpich
M. Golpich
Long non-coding RNAs (lncRNAs) are biomarkers for diagnosis and treatment of Parkinson’s disease (PD). Since dopaminergic cell transplantation is a clinical method to treat PD, this study investigated the effects of dopaminergic cell therapy on the expression of some lncRNAs and genes related to PD. In this study, Twenty-eight rats were randomly assigned to four experimental groups. The control group (Sal group) received saline injections. The Par group was a PD rat model with 6-hydroxydopamine (6-OHDA) injection in right striatum (ST). PD animals were transplanted by undifferentiated P19 stem cells (Par-E group), and P19-derived dopaminergic cells (Par-N group). Cell transplant effects were evaluated using behavioral tests (cylinder, open field, and rotarod tests), and histological methods (H&E and Nissl staining, and immunohistochemistry). Moreover, the expression of lncRNAs MALAT1, MEG3, and SNHG1, alongside specific neuronal (synaptophysin) and dopaminergic (tyrosine hydroxylase) markers was evaluated by qRT-PCR. Behavioral and histopathological examinations revealed that cell transplantation partially compensated dopaminergic cell degeneration in ST and substantia nigra (SN) of PD rats. The expression of MALAT1, SNHG1, and MEG3 was decreased in the ST of the Par group, while MEG3 and SNHG1 gene expression was increased in PBMC relative to the Sal group. In PBMC of the Par-N group, all three lncRNAs showed a reduction in their expression. Conversely, MALAT1 and SNHG1 expression was increased in ST tissue, while MEG3 gene expression was decreased compared to the Sal group. In conclusion, dopaminergic cell transplantation could change the lncRNAs expression. Furthermore, it partially improves symptoms in PD rats.

1 January 2020 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MEM. Ebrahiminia
M. Ebrahiminia
FEFariba Esmaeili
Fariba Esmaeili
LSL. Shabani
L. Shabani

21 February 2022 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
SMS. Mansourzadeh
S. Mansourzadeh
FEFariba Esmaeili
Fariba Esmaeili
LSL. Shabani
L. Shabani
SGShima Gharibi
Shima Gharibi
Medicago sativa L. is a medicinal herb first cultivated in ancient Iran. Traditionally, it has been utilized for the treatment of several disorders. The plant has been in the human diet for at least 1500 years. Although the hypoglycaemic and anti-diabetic effects of the plant have been approved in traditional medicine, further investigations are needed to support the rational use of M. sativa by humans. This project aimed to evaluate the trans-differentiation potential of bone marrow mesenchymal stem cells (MSCs) to pancreatic β-like cells (insulin-producing cells; IPCs) under the influence of M. sativa extract. Bone marrow MSCs isolated, characterized, and then treated by flower or leaf extract of M. sativa. Beta-cell characteristics of the differentiated cells were evaluated by several techniques, including specific staining, QPCR, immunofluorescence, and ELISA. The results showed that the differentiated cells were able to express some specific pancreatic genes (PDX-1, insulin1, and insulin2) and proteins (insulin receptor beta, insulin, proinsulin, and C peptide). Furthermore, ELISA analysis indicated the ability of these cells in the production and secretion of insulin, after exposure to glucose. Overall, both the flower and leaf extract of M. sativa had the potential of differentiation induction of MSCs into IPCs with the characteristics of pancreatic β–like cells. Therefore, M. sativa, as an herbal drug, may be beneficial for the treatment of diseases including diabetes.